Recommendations to improve cultural and linguistic diversity in clinical trials

ACTA has prepared a set of recommendations aimed at enhancing clinical trial engagement, involvement, and participation for people from culturally and linguistically diverse (CALD) backgrounds. These recommendations have been submitted to the Department of Health as part of the efforts to promote cultural diversity in clinical trials.

It should be noted that these recommendations have been developed to address the broader sector. While ACTA intends to identify and implement some of these recommendations in the future, there is currently no operational plan for their implementation in this document.

Extensive consultations with consumers and researchers, including members of ACTA’s Consumer Engagement, Equity, and Diversity Working Group, informed the formulation of these recommendations. The recommendations underwent a four-week sector consultation period from March-April, during which feedback and insights were provided by stakeholders. All responses and suggestions have been carefully considered in the final version of the recommendations.

The completion of this work was made possible by the generous funding provided by the Medical Research Future Fund (MRFF). ACTA remains committed and enthusiastic about promoting diversity and inclusivity in clinical trials and looks forward to continuing this important work.

Thank you to those who have provided feedback on the draft during the consultation period. We invite you to access the final document by clicking on the following link. If you have any questions or comments on this work, please feel free to contact ACTA via email at acta@clinicaltrialsalliance.org.au.